BR112012007332B1 - Composição farmacêutica que compreende um macrólido imunossupressor e seu método de preparo - Google Patents

Composição farmacêutica que compreende um macrólido imunossupressor e seu método de preparo Download PDF

Info

Publication number
BR112012007332B1
BR112012007332B1 BR112012007332-0A BR112012007332A BR112012007332B1 BR 112012007332 B1 BR112012007332 B1 BR 112012007332B1 BR 112012007332 A BR112012007332 A BR 112012007332A BR 112012007332 B1 BR112012007332 B1 BR 112012007332B1
Authority
BR
Brazil
Prior art keywords
pharmaceutical composition
composition according
tacrolimus
component
skin
Prior art date
Application number
BR112012007332-0A
Other languages
English (en)
Portuguese (pt)
Other versions
BR112012007332A2 (pt
Inventor
Alexandra Sabine Bãrbel Gobel
Original Assignee
Bay Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bay Pharma Gmbh filed Critical Bay Pharma Gmbh
Publication of BR112012007332A2 publication Critical patent/BR112012007332A2/pt
Publication of BR112012007332B1 publication Critical patent/BR112012007332B1/pt

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N1/00—Sampling; Preparing specimens for investigation
    • G01N1/28—Preparing specimens for investigation including physical details of (bio-)chemical methods covered elsewhere, e.g. G01N33/50, C12Q
    • G01N1/40—Concentrating samples
    • G01N1/4055—Concentrating samples by solubility techniques
    • G01N2001/4061—Solvent extraction

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Transplantation (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
BR112012007332-0A 2009-10-08 2010-10-07 Composição farmacêutica que compreende um macrólido imunossupressor e seu método de preparo BR112012007332B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP09012724A EP2308468A1 (en) 2009-10-08 2009-10-08 Novel pharmaceutical composition comprising a macrolide immunosuppressant drug
EP09012724.2 2009-10-08
PCT/EP2010/064965 WO2011042485A1 (en) 2009-10-08 2010-10-07 Novel pharmaceutical composition comprising a macrolide immunosuppressant drug

Publications (2)

Publication Number Publication Date
BR112012007332A2 BR112012007332A2 (pt) 2016-10-04
BR112012007332B1 true BR112012007332B1 (pt) 2021-07-13

Family

ID=41435414

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012007332-0A BR112012007332B1 (pt) 2009-10-08 2010-10-07 Composição farmacêutica que compreende um macrólido imunossupressor e seu método de preparo

Country Status (12)

Country Link
US (1) US8574562B2 (https=)
EP (2) EP2308468A1 (https=)
JP (1) JP5764792B2 (https=)
KR (1) KR101790257B1 (https=)
CN (1) CN102510752B (https=)
AU (1) AU2010305404B2 (https=)
BR (1) BR112012007332B1 (https=)
CA (1) CA2774720C (https=)
ES (1) ES2552803T3 (https=)
IN (1) IN2012DN01559A (https=)
MX (1) MX2012003800A (https=)
WO (1) WO2011042485A1 (https=)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10265265B2 (en) 2007-03-15 2019-04-23 Drug Delivery Solutions Limited Topical composition
WO2012176865A1 (ja) * 2011-06-23 2012-12-27 参天製薬株式会社 ヒアルロン酸またはその塩およびプロピレングリコールを含有する点眼液
WO2014117035A1 (en) 2013-01-24 2014-07-31 Transderm, Inc. COMPOSITIONS FOR TRANSDERMAL DELIVERY OF mTOR INHIBITORS
CN103830178B (zh) * 2014-03-18 2017-01-11 深圳劲创生物技术有限公司 一种蒜氨酸微乳及其制备方法和应用
RU2737893C2 (ru) * 2015-08-11 2020-12-04 Айсью Медсинз Б.В. Пэгилированная липидная наночастица с биоактивным липофильным соединением
JP6932180B2 (ja) * 2016-04-04 2021-09-08 エムシー２・セラピューティクス・リミテッドＭＣ２ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｌｉｍｉｔｅｄ タクロリムスを含む局所組成物
KR20190016036A (ko) * 2016-06-03 2019-02-15 아벡신 에이에스 다중불포화 케톤 및 칼시뉴린 억제제를 포함하는 조합 치료요법
CN106074386A (zh) * 2016-08-31 2016-11-09 佛山市弘泰药物研发有限公司 一种依维莫司自微乳制剂及其制备方法
EP3515422A1 (en) 2016-09-21 2019-07-31 Avexxin AS Pharmaceutical composition
JP7108631B2 (ja) 2017-01-06 2022-07-28 パルヴェラ セラピューティクス、インク． ｍＴＯＲ阻害剤の無水組成物およびその使用方法
WO2019060696A1 (en) 2017-09-25 2019-03-28 Surface Pharmaceuticals, Inc. OPTHALMIC PHARMACEUTICAL COMPOSITIONS AND METHODS FOR THE TREATMENT OF OCULAR SURFACE DISEASE
EP3542788A1 (en) 2018-03-19 2019-09-25 MC2 Therapeutics Limited Topical composition comprising calcipotriol and betamethasone dipropionate
WO2019233722A1 (en) 2018-06-08 2019-12-12 Almirall, S.A. Pharmaceutical composition comprising tacrolimus
US11000513B2 (en) 2018-07-02 2021-05-11 Palvella Therapeutics, Inc. Anhydrous compositions of mTOR inhibitors and methods of use
CA3124945A1 (en) 2018-12-27 2020-07-02 Surface Ophthalmics, Inc. Ophthalmic pharmaceutical compositions and methods for treating ocular surface disease
CA3164846A1 (en) * 2020-01-22 2021-07-29 Nayan Desai Topical compositions comprising a macrolide immunosuppressant
TWI769745B (zh) * 2021-03-19 2022-07-01 國泰醫療財團法人國泰綜合醫院 醫藥組成物與製藥用途
US12310981B2 (en) 2021-05-10 2025-05-27 Surface Ophthalmics, Inc. Use of chondroitin sulfate for relieving ocular pain
US12440510B2 (en) 2021-05-10 2025-10-14 Surface Ophthalmics, Inc. Use of chondroitin sulfate for relieving ocular pain
BE1030538B1 (nl) 2022-05-18 2023-12-19 Bogaert Gina Van Liposomaal preparaat met ingekapselde hormonen, werkwijze voor de productie en gebruik ervan
KR102727647B1 (ko) * 2023-11-28 2024-11-08 장병모 칼시뉴린 억제제를 포함하는 피부질환의 예방 또는 치료용 약학적 조성물

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PH26083A (en) * 1987-11-09 1992-02-06 Sandoz Ltd 11, 28-dioxa-4-azatricyclo [22.3.1.04.9) octacos-18-ene derivatives and pharmaceutical compositions containing them and method of use thereof
GB2222770B (en) * 1988-09-16 1992-07-29 Sandoz Ltd Pharmaceutical compositions containing cyclosporins
CH686761A5 (de) * 1993-05-27 1996-06-28 Sandoz Ag Galenische Formulierungen.
GB2315216B (en) * 1993-10-05 1998-10-14 Ciba Geigy Ag Microemulsion preconcentrates comprising FK506 or 33-epi-chloro-33-desoxy-ascomycin
ATE299017T1 (de) * 1994-10-26 2005-07-15 Novartis Pharma Gmbh Arzneimittel
GB9723669D0 (en) * 1997-11-07 1998-01-07 Univ Aberdeen Skin penetration enhancing components
DE10036871A1 (de) * 2000-07-28 2002-02-14 Pharmasol Gmbh Dispersionen zur Formulierung wenig oder schwer löslicher Wirkstoffe
IL161588A0 (en) * 2001-11-01 2004-09-27 Yissum Res Dev Co Method and composition for dry eye treatment
HUP0402318A3 (en) * 2001-12-14 2012-09-28 Jagotec Ag Pharmaceutical composition comprising cyclosporin and use thereof
AU2005263551B2 (en) * 2004-07-16 2009-04-09 Novartis Ag Use of a steroid for enhancement of skin permeability
EP1929996B1 (en) * 2004-11-09 2011-02-16 Novagali Pharma S.A. Ophthalmic emulsions containing an immunosuppressive agent
KR100678829B1 (ko) * 2004-12-06 2007-02-05 한미약품 주식회사 타크로리무스의 경구용 마이크로에멀젼 조성물
EP1848407A2 (en) * 2005-02-02 2007-10-31 Mega Lifesciences Pvt. Ltd. Oral pharmaceutical composition
US8663639B2 (en) * 2005-02-09 2014-03-04 Santen Pharmaceutical Co., Ltd. Formulations for treating ocular diseases and conditions
JP4974903B2 (ja) * 2005-02-09 2012-07-11 参天製薬株式会社 疾患または状態を処置するための液体処方物

Also Published As

Publication number Publication date
US20120184511A1 (en) 2012-07-19
KR20120093865A (ko) 2012-08-23
IN2012DN01559A (https=) 2015-06-05
EP2485714A1 (en) 2012-08-15
CN102510752A (zh) 2012-06-20
CA2774720A1 (en) 2011-04-14
ES2552803T3 (es) 2015-12-02
BR112012007332A2 (pt) 2016-10-04
AU2010305404B2 (en) 2015-04-02
WO2011042485A1 (en) 2011-04-14
JP5764792B2 (ja) 2015-08-19
CN102510752B (zh) 2015-08-05
AU2010305404A1 (en) 2012-03-08
JP2013507337A (ja) 2013-03-04
EP2308468A1 (en) 2011-04-13
US8574562B2 (en) 2013-11-05
KR101790257B1 (ko) 2017-10-26
CA2774720C (en) 2017-05-23
MX2012003800A (es) 2012-06-28
EP2485714B1 (en) 2015-09-09

Similar Documents

Publication Publication Date Title
CA2774720C (en) Pharmaceutical composition comprising a macrolide immunosuppressant drug
Ashara et al. Micro-emulsion based emulgel: a novel topical drug delivery system
EP2345414A1 (en) Tacrolimus preparation for external applications
Wang et al. Integrating tacrolimus into eutectic oil-based microemulsion for atopic dermatitis: Simultaneously enhancing percutaneous delivery and treatment efficacy with relieving side effects
JP2005516931A (ja) シクロスポリンを含む医薬製剤およびその使用
WO2016198469A1 (en) Penetration of alpha-hydroxy acids from water-free emulsions
US20220362148A1 (en) Isotretinoin formulations and uses and methods thereof
JP2011102260A (ja) タクロリムス外用剤
HK1167102A (en) Novel pharmaceutical composition comprising a macrolide immunosuppressant drug
Manjula Development and Evaluation of Membrane Moderated Therapeutic Systems and Liposomal Systems as Carriers for Transdermal Delivery of Few Novel Nsaid’s
Indira Proniosomes as a Carrier System for Transdermal Drug Delivery of Non Steroidal Anti-Inflamatory Drug
Shilpa Comparative Evalution of Transdermal Patches of Lornoxicam Using Natural Semi–Synthetic and Synthetic Polymers
Al-Fagih Transdermal Delivery System of Testosterone Using Solid Lipid Particles

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06T Formal requirements before examination [chapter 6.20 patent gazette]
B25A Requested transfer of rights approved

Owner name: REINARD NEUBERT (DE) ; JOHANNES WOHLRAB (DE)

B25A Requested transfer of rights approved

Owner name: SKINOMICS GMBH (DE)

B25A Requested transfer of rights approved

Owner name: BAY PHARMA GMBH (DE)

B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 07/10/2010, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO.